Nuvalent, Inc. (NUVL): Price and Financial Metrics
NUVL Price/Volume Stats
| Current price | $63.06 | 52-week high | $89.39 |
| Prev. close | $64.25 | 52-week low | $31.09 |
| Day low | $62.65 | Volume | 624,400 |
| Day high | $64.32 | Avg. volume | 434,741 |
| 50-day MA | $78.62 | Dividend yield | N/A |
| 200-day MA | $62.35 | Market Cap | 4.04B |
NUVL Stock Price Chart Interactive Chart >
Nuvalent, Inc. (NUVL) Company Bio
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Latest NUVL News From Around the Web
Below are the latest news stories about NUVALENT INC that investors may wish to consider to help them evaluate NUVL as an investment opportunity.
Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL)On December 18, 2023, Director Anna Protopapas executed a sale of 5,000 shares of Nuvalent Inc (NASDAQ:NUVL), according to a recent SEC Filing. |
Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL)Nuvalent Inc (NASDAQ:NUVL), a company specializing in the development of precisely targeted therapies for patients with cancer, has reported an insider sale according to a recent SEC filing. |
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 7:30 a.m. PT in San Francisco. |
Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline ProgressCompany Strengthens Cash Position and Advances Clinical Trials |
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial ResultsNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress and reported third quarter 2023 financial results. |
NUVL Price Returns
| 1-mo | -20.89% |
| 3-mo | -16.39% |
| 6-mo | 23.50% |
| 1-year | 87.90% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -14.31% |
| 2023 | 147.11% |
| 2022 | 56.41% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...